Table I.
Patient characteristics and clinical outcome.
| Patient number | Gender | Age, years | Primary location | Positive lymph node | Response rate (first-line chemotherapy) | Disease-free survival, days | Overall survival, days |
|---|---|---|---|---|---|---|---|
| 23 | Male | 60 | Rectum | 4 | PR | 1125 | 449 |
| 24 | Female | 64 | Colon | 2 | SD | 594 | Alive |
| 25 | Male | 60 | Rectum | 4 | PD | 403 | 126 |
| 26 | Female | 59 | Rectum | / | SD | 518 | Alive |
| 27 | Male | 73 | Colon | 0 | PD | 1212 | 74 |
| 28 | Female | 51 | Rectum | 0 | PD | 814 | 64 |
| 29 | Female | 69 | Rectum | 2 | PD | 1096 | Alive |
| 30 | Male | 68 | Colon | / | PR | / | 852 |
| 31 | Male | 37 | Colon | / | PR | / | 420 |
| 32 | Female | 57 | Rectum | / | PR | / | Alive |
The use of ‘/’ refers to patients who had metastatic disease at first diagnosis and therefore surgery could not be performed, so the information regarding lymph nodes is absent. ‘Disease-free survival’ refers to the days between primary surgery and relapse, and ‘overall survival’ refers to the days between the salvage chemotherapy and disease progression. PR, partial response; SD, stable disease; PD, progressive disease.